Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.64 |
| ▸ | CTRC | Q99895 | 1/20 | 0.64 |
| ▸ | AGER | Q15109 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 14/20 | 0.57 |
| ▸ | MAOB | P27338 | 14/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19851004 | 0.85 | AGER (0.70) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29276772 | 0.83 | AGER (0.75) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19851002 | 0.83 | MEN1 (0.70) | CTRB1CTRCNPC1RAB9AMEN1 | |
| SCHEMBL6310060 | 0.82 | CTRB1 (0.64) | CTRB1CTRCAGERNPC1RAB9A | |
| SCHEMBL14355161 | 0.82 | MAOA (0.60) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30294204 | 0.82 | MAOA (0.60) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL14531586 | 0.82 | MAOA (0.60) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7113308 | 0.81 | CYP1B1 (0.67) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28712020 | 0.80 | CYP1A1 (0.68) | CTRB1CTRCAGERNPC1RAB9A | |
| SCHEMBL28908960 | 0.79 | AGER (0.62) | AGERNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947207-B2 | GP130 modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190292161-A1 | GP130 MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-09-26 | — | — | US | disclosed |
| WO-2018027193-A1 | GP130 MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292161-A1 | GP130 MODULATORS | GRIN2A, GRIA4, GRIA3 | CTRB1 4385/4885CTRC 4738/4885AGER 67/4885 |
| US-10947207-B2 | GP130 modulators | GRIN2A, GRIA4, GRIA3 | CTRB1 4385/4885CTRC 4738/4885AGER 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.